Metabolic dysfunction-associated steatotic liver disease (MASLD) are widely prevalent and progressive diseases. Patients with MASLD are at risk of developing liver fibrosis, which could lead to hepatocellular carcinoma or cirrhosis of the liver. Despite their prevalence, no FDA-approved pharmacological treatments exist for these conditions. 

Advances in translational research have led to significant breakthroughs, including the creation of novel mouse models to test potential drugs and assess the progression of MASLD, pioneering imaging techniques aimed at replacing invasive biopsy procedures and integrating computational models to refine the design of clinical trials. Together, these advancements have enriched our understanding of the underlying pathophysiology of MASLD. As a result of these insights, several innovative chemical compounds have entered late-phase clinical trials in the past decade, showing promising potential for securing FDA approval. 

This Methods Collection aims to highlight novel translational methodologies that have contributed significantly to understanding MASLD pathophysiology. This collection will bring together unique approaches employed during preclinical and clinical developmental phases, thereby addressing the obstacles encountered in drug discovery for these conditions.